Senn Lisa, Wehmeier Caroline, Hönger Gideon, Geiger Irene, Amico Patrizia, Hirt-Minkowski Patricia, Steiger Jürg, Dickenmann Michael, Schaub Stefan
Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland.
HLA-Diagnostics and Immungenetics, Department of Laboratory Medicine, University Hospital Basel, Basel, Switzerland.
Front Med (Lausanne). 2021 Aug 2;8:724851. doi: 10.3389/fmed.2021.724851. eCollection 2021.
Few data on husband-to-wife transplantations with mutual children (H2W) exist in the current era. We investigated the outcome of H2W transplantations ( = 25) treated with T cell-depleting induction compared to women with prior pregnancies also receiving their first HLA-mismatched kidney transplant, but from a different donor source: (i) other living donor ( = 52) and (ii) deceased donor ( = 120). Seventy-four percent of the women had ≥2 pregnancies; median follow-up time was 5 years. Death-censored allograft survival was significantly lower in the H2W group compared to the other two groups ( = 0.03). Three of four graft losses in the H2W group were due to rejection. 5-year patient survival in the H2W group was high and similar compared to the other living donor group (100 vs. 98%; = 0.28). The incidence of (sub)clinical antibody-mediated rejection was higher in the H2W group (36 vs. 20 vs. 18%) ( = 0.10). The frequency of infections was similar among the three groups. No immunological parameter was predictive for rejection or graft loss in H2W transplantations. In conclusion, H2W transplantation is a valuable option, but associated with a higher risk for allograft loss due to rejection despite T cell-depleting induction. Further research is required for better risk prediction on an individual patient level.
在当今时代,关于有共同子女的夫妻间肾移植(夫供妻肾移植)的数据很少。我们研究了接受去除T细胞诱导治疗的25例夫供妻肾移植患者的结局,并与既往有过妊娠且首次接受HLA配型不相合肾移植的女性进行比较,但后者的供体来源不同:(i)其他活体供体(52例)和(ii) deceased donor(120例)。74%的女性有≥2次妊娠;中位随访时间为5年。与其他两组相比,夫供妻肾移植组的死亡删失移植物存活率显著较低(P = 0.03)。夫供妻肾移植组的4例移植物丢失中有3例是由于排斥反应。夫供妻肾移植组的5年患者存活率较高,与其他活体供体组相似(100%对98%;P = 0.28)。夫供妻肾移植组(亚)临床抗体介导排斥反应的发生率较高(36%对20%对18%)(P = 0.10)。三组间感染频率相似。在夫供妻肾移植中,没有免疫参数可预测排斥反应或移植物丢失。总之,夫供妻肾移植是一种有价值的选择,但尽管进行了去除T细胞诱导治疗,仍与因排斥反应导致移植物丢失的较高风险相关。需要进一步研究以在个体患者水平上进行更好的风险预测。 (注:“deceased donor”未明确准确中文表述,暂保留英文)